During the pandemic, it became evident to hospital groups that having a partner that can offer a broad portfolio was a key advantage. We are currently…
In Conversation
While scaling our company by uniting with others would make us more competitive on a global scale, we still believe it is possible to be successful…
We are trying to overcome the idea that robotic systems are difficult to adopt with a steep learning curve; they can improve the clinical outcomes of…
We are calling strongly for a greater role in ensuring that the right treatments are approved, the ones that matter most to patients. The only way…
The main differentiating factor for Abdi Ibrahim among Turkish companies is our willingness to invest in, and collaborate with, international players
We are close to having the technological capacity to develop all types of biosimilar products, even some novel ones
The medical infrastructure in Turkey is substantial with many large hospitals. However, for clinical trials, we need more dedicated places to conduct clinical trials, an institutional…
Almost 50 percent of clinical trials in the region last year were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led…
The Turkish authorities continue to be content with the current [pricing] system because it has been sustained until today. The question the industry is asking itself…
Putting the childhood cancer agenda under the spotlight is especially relevant today, as the world’s focus has shifted almost exclusively to COVID. We must continue to…
I always come back to the question of how we help as many patients as possible access the healthcare solutions they need. Within this push, collaboration…
The objective [for Turkey] now should be to implement policies in areas like rare diseases so that we can expedite access to innovative medicines for diseases…
